Chen N, Qian MJ, Zhang RH, Gao QQ, He CC, Yao YK, Zhou JY, Zhou H. Tislelizumab-related enteritis successfully treated with adalimumab: A case report. World J Clin Cases 2022; 10(28): 10186-10192 [PMID: 36246838 DOI: 10.12998/wjcc.v10.i28.10186]
Corresponding Author of This Article
Hua Zhou, MD, Associate Chief Physician, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. zhouhua1@zju.edu.cn
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Na Chen, Chao-Chao He, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Min-Jia Qian, Ru-Hui Zhang, Ya-Ke Yao, Jian-Ying Zhou, Hua Zhou, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Min-Jia Qian, Department of Critical Care Medicine, Zhuji People’s Hospital, Shaoxing 311800, Zhejiang Province, China
Qi-Qi Gao, Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Chao-Chao He, Department of Pharmacy, Yiwu Central Hospital, Jinhua 322000, Zhejiang Province, China
Author contributions: All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hua Zhou, MD, Associate Chief Physician, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. zhouhua1@zju.edu.cn
Received: April 22, 2022 Peer-review started: April 22, 2022 First decision: June 8, 2022 Revised: June 17, 2022 Accepted: August 25, 2022 Article in press: August 25, 2022 Published online: October 6, 2022 Processing time: 155 Days and 21.4 Hours
Abstract
BACKGROUND
With programmed death-1 (PD-1) inhibitors becoming the standard treatment for lung cancer, PD-1-related adverse reactions and treatment have gradually become prominent.
CASE SUMMARY
First reported case of tislelizumab-related enteritis successfully treated with adalimumab 40mg every 2 wk for 3 times in an advanced lung cancer patient who received first-line tislelizumab/pemetrexed/carboplatin for 4 cycles. The patient continued receiving the treatment of pemetrexed/carboplatin after symptoms, abdominal computed tomography and colonoscopy improved, significant diarrhea was not occurred.
CONCLUSION
Adalimumab can be an effective treatment option for patients with PD-1 antibody related enteritis if they do not respond well to glucocorticoid treatment.
Core Tip: A patient with advanced lung cancer who developed diarrhea after receiving tislelizumab combined with pemetrexed and carboplatin, with poor response to glucocorticoid treatment. The symptoms were significantly improved after the use of adalimumab 10 mg, subcutaneous injection, every 2 wk for 3 times. Colonoscopy and intestinal mucosal pathology suggested improvement.
